AMT takes speedy second chance on Glybera in Europe
This article was originally published in Scrip
Executive Summary
Amsterdam Molecular Therapeutics has requested a re-examination of the marketing authorisation approval application for its lead product, Glybera (alipogene tiparvovec), with the EMA, despite being turned down as recently as 24 June (scripintelligence.com, 24 June).